Inovio Pharmaceuticals, Inc. (INO) is a Healthcare stock trading at $1.18 (as of 2026-08-21), with a market capitalization of $122.01M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals develops DNA medicines to treat and protect against diseases associated with HPV, cancer, and infectious diseases, using precisely designed SynCon sequences and CELLECTRA smart devices to deliver DNA plasmids, with revenue from collaborative arrangements shown as 0.0 in the latest period provided.
The companys profit model depends on whether its DNA medicines progress through clinical studies with clinically meaningful outcomes, and then achieve commercialization, since there is no revenue reported in the latest period provided and the operating performance remains deeply negative.
Business quality (Weak): Clear clinical efficacy metrics are being tracked, but the latest reported revenue is 0.0 and the operating margin is deeply negative, so near-term financial leverage appears limited until later-stage progress and commercialization.
| Price | $1.18 |
| Market Cap | $122.01M |
| Price / Book | 27.91 |
| FCF Yield | -124.8% |
| Revenue (TTM) | $65343.00 |
| Net Margin | -130000.0% |
| Revenue Growth (YoY) | -70.0% |
| EPS Growth (YoY) | -54.2% |
| FCF Growth (YoY) | -15.0% |
| Altman Z-Score | -36.80 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | FMR LLC ($16.25M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jacqueline E. Shea |
| Employees | 134 |
| Country | US |
| IPO Date | 1998-12-08 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.